October 27, 2014 / 5:53 PM / in 3 years

BUZZ-Aurinia Pharmaceuticals: Canaccord starts with "buy"

** Drug developer’s shares up 11 pct at $3.24

** Canaccord Genuity analysts started coverage of stock with “buy” rating and $10 price target

** Analysts believe Aurinia’s drug for inflammatory disease Lupus could peak at $630 million in the United States, if approved

** Company currently running mid-stage trials on drug

** Stock has fallen more than 12 pct in last six months

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below